Scholars Central

Case reportPublished 2017

Neonatal Diabetes-From Insulin to Oral Hypoglycemic Agent: Case Report

Authors: Sridevi A Naaraayan, Poovazhagi Varadharajan, Raghavan V Dhakshayani, Rema Chandramohan

Diabetes Case Reports

Volume 2 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes that occurs in first 6 months of life with an incidence of 1 in 100,000 to 500,000 live births [1]. It is one of the disorders in which the role of genetic analysis is not limited to confirmation of the diagnosis, but also required for selecting the appropriate therapy. Patients with certain mutations like the ones involving KCNJ11 and ABCC8 genes respond to oral sulfonylurea [2]. Successful switch over from subcutaneous insulin to oral sulfonylurea has been previously reported by various authors [3,4]. In this case report, we present our experience on transferring three patients with genetic mutations from insulin to oral glibenclamide in last three years.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Diabetes Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDiabetes Case Reports
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Sridevi A Naaraayan”
  • BylineArticles whose byline prints “Poovazhagi Varadharajan”
  • BylineArticles whose byline prints “Raghavan V Dhakshayani”
  • BylineArticles whose byline prints “Rema Chandramohan”